Anion-Exchange High-Performance Liquid Chromatography (AEX-HPLC)

Anion-exchange chromatography (AEX-HPLC) separates analytes based on differences in effective surface charge density and electrostatic interactions with a positively charged stationary phase. In CMC, AEX is widely used for AAV to separate empty/partial/full capsids and quantify % full (often with dual-wavelength UV at 260/280 nm), and it is also used for nucleic acids (e.g., plasmid DNA isoforms). For therapeutic proteins, ion-exchange chromatography (IEC) is standard for charge variants, most commonly cation-exchange (CEX) for mAbs, with AEX used when the protein is net-negative under the chosen conditions. Regulators expect fit-for-purpose, orthogonal methods; they do not prescribe a single assay (e.g., AEX vs AUC) for AAV capsid content.

• Legacy: Low-pressure IEC on soft gels (e.g., DEAE-Sepharose).

• Established practice: High-pressure IEC (CEX/AEX) on rigid supports; AEX is a mainstay for AAV empty/full, while CEX is typically used for mAb charge variants in QC.

• Emerging/orthogonal: IEC–MS workflows using volatile buffers (often pH-gradient CEX-MS) for intact-level variant ID without offline fractionation.

Analytes with net negative charge bind to quaternary-ammonium (QA) or similar AEX ligands at selected pH/ionic strength. Increasing salt (e.g., NaCl) or changing pH weakens electrostatic interactions and elutes species according to effective charge density, providing charge-based separation.

For small charged molecules such as nucleoside triphosphates (NTPs), elution order correlates with the number of phosphate groups and overall charge density.

For large biomolecules, separation reflects not only total charge but also how that charge is presented spatially (e.g., molecular conformation and topology).

• Chromatogram: Detector response vs time (or salt/pH).

• Proteins: Integrate acidic/main/basic regions; compare to spec/trending rules.

• AAV: Integrate empty/partial/full peaks; dual UV (260/280 nm) helps confirm DNA-containing peaks; expect method-dependent bias vs other techniques—hence need for orthogonal confirmation.

• mRNA Process Impurities: Identify and integrate early-eluting peaks corresponding to residual NTPs (ATP, GTP, CTP, UTP) and capping analogs. These small, lower-charge molecules elute early in the salt gradient, distinct from the highly charged mRNA product (which elutes much later or in a high-salt strip step).

• High resolution for closely related variants.

• Robust/quantitative relative abundance with validated integration regions.

• Versatile across proteins, viral vectors, and nucleic acids; AEX is scalable for AAV.

• Method development complexity: Gradient, pH, and salt selection can be time-consuming; serotype-specific for AAV.

• Identification is indirect: Requires MS or orthogonal analytics to assign chemistry behind peaks.

• Secondary interactions: Non-ionic interactions can affect peak shape/recovery; partially filled/misassembled AAV may co-elute.

• Inter-method variability: Different techniques (AEX, AUC, MP, CD-MS) can give different % full; agencies stress orthogonality and justification.

• For mRNA applications: AEX methods for NTP quantification require careful gradient optimization to resolve structurally similar nucleotides. The method detects only charged small-molecule impurities—it does not provide information about mRNA integrity or sequence variants.

• Specificity & peak ID: Confirm main/variant regions (proteins) and empty/partial/full assignments (AAV), e.g., by fraction-MS or orthogonal methods.

• Resolution/system suitability: Define minimum resolution between critical pairs (e.g., main vs acidic; empty vs full) and monitor column performance.

• Precision: Demonstrate low RSD for integrated regions or % full.

• Robustness: Probe small deliberate changes (pH, salt type, gradient slope, temperature).

• Orthogonality: Cross-check with AUC/MP/CD-MS/SEC-MALS for AAV; with icIEF/CEX-MS for proteins.

Use a product-specific reference standard as the primary system control. For protein methods, the NISTmAb (RM 8671) is widely used during development and system suitability to benchmark retention/resolution and method performance.

For AAV, qualify in-house empty/partial/full controls (well-characterized by orthogonal methods) to set integration masks and verify 260/280 assignment; trend column health and critical resolution over lifetime.

For plasmids, dedicated AEX pDNA analytical columns support rapid, reproducible isoform separation for in-process and release testing. Although both plasmid DNA and mRNA are polyanionic, AEX is effective for plasmid isoform separation because different topological forms (supercoiled, open circular, linear) present markedly different effective charge densities and surface interactions. In contrast, mRNA integrity variants are primarily linear polymers that differ mainly in length, not topology or charge distribution, and therefore exhibit highly similar AEX behavior and poor chromatographic resolution.

• mAbs & proteins: Routine IEC (commonly CEX) for charge variants; AEX applied when analyte is net-negative at method pH.
• AAV gene therapy: AEX is a widely used, scalable approach for empty/partial/full separation and is often used for release—not mandated; orthogonal confirmation recommended.
• Oligonucleotides & plasmids: AEX is a primary platform for purification and analytical assessment (e.g., pDNA isoforms).
• mRNA / LNP:
  Process-Related Impurities: AEX-HPLC with UV detection (260 nm) is used to quantify residual nucleoside triphosphates (NTPs: ATP, CTP, GTP, and modified UTP such as N1-methylpseudouridine-TP) and cap analogs remaining from the in vitro transcription (IVT) reaction. Separation is achieved using a salt gradient - weakly charged species elute first, while more highly charged species (e.g., cap analogs with additional phosphate groups) elute later.
  Note: AEX-HPLC separates small molecule impurities by charge. It is not typically used for mRNA integrity or purity profiling, those applications require Ion-Pair RP-HPLC (IP-RP) or capillary electrophoresis (CE).